StemRIM

Tokyo Stock Exchange 4599.T

StemRIM Revenue for the year ending July 31, 2024: USD 0.00

StemRIM Revenue is USD 0.00 for the year ending July 31, 2024, a -100.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

StemRIM Revenue for the year ending July 31, 2023 was USD 16.51 M, a 9,477.91% change year over year.
StemRIM Revenue for the year ending July 31, 2022 was USD 172.41 K, a -98.65% change year over year.
StemRIM Revenue for the year ending July 31, 2021 was USD 12.76 M, a -35.61% change year over year.
StemRIM Revenue for the year ending July 31, 2020 was USD 19.82 M, a 2,056.67% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Tokyo Stock Exchange: 4599.T

StemRIM

CEO	Mr. Masatsune Okajima
IPO Date	Aug. 9, 2019
Location	Japan
Headquarters	Saito Bio-Incubator
Employees	45
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Key trends

Past 5 years